Posted by Marty on September 23, 2008, at 18:44:01
In reply to agomelatine doesn't cause sexual dysfunction, posted by rotem on September 23, 2008, at 17:40:42
> can we do something to hurry it's marketing?
> I can't wait.
---
Funny you ask. I asked myself the same question. A petition (with signatures in the thousands.. ~2000?) and a clever open letter endorsed by one or two Psychiatrists (preferably 1 from Europe(France) and 1 from USA) that we would try to get published in the best medical journal we could .. that could be helpful to Servier/Novartis.I think it's feasable. The main point of the open letter to the EMEA/FDA could be the need for more atypical antidepressants for treatment resistant people. The EMEA/FDA wants to approve meds that are proven superior to the one already on the market and that's a bad thing for treatment resistant / treatment intolerant people. I don't care if an -ATYPICAL- AD works only for 20% of the people since those AREN'T marketed as first line treatment. What's count is to have as much as different ADs with different mechanism of action that we can! .... that said, Agomelatine has been proven superior to Paroxetine and Sertraline in a couple of trials but doubts will remain as long as Servier doesn't finance more trials. My opinion ? Agomelatine is pretty safe and the EMEA/FDA shouldn't care much about more trials to confirm superiority of it: Even if it works on 2 time LESS people than Paroxetine or Sertraline IT DOESN'T MATTER SINCE IT'S A NEW CLASS OF ATYPICAL ANTIDEPRESSANT. People are waiting in suffering for those atypicals.. could they wait for the next in the SAME CLASS before bitching about superiority ?
/\/\arty
poster:Marty
thread:851906
URL: http://www.dr-bob.org/babble/20080915/msgs/853680.html